VCYT Stock Analysis: Veracyte | NASDAQ
Diagnostics & Research | NASDAQ, USA | Market Cap: 4.555m USD | 12M Return: 107% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 72.8M
Qual. Beats: 1
Rev. Trend: 99.7%
Qual. Beats: 5
Warnings
No concerns identified
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Veracyte, Inc. (NASDAQ: VCYT) is a molecular diagnostics company headquartered in South San Francisco, California, operating in the United States and internationally. Founded in 2006 under the name Calderome, Inc., the company adopted its current name in March 2008 and went public in October 2013. It is classified within the Health Care sectors Biotechnology sub-industry, with a mid-cap market valuation.
The companys business model centers on developing and commercializing genomic classifiers and molecular tests that aid in the diagnosis and risk stratification of various cancers. Its test menu includes the Afirma Genomic Sequencing Classifier for thyroid nodules, the Decipher Prostate and Decipher Bladder Genomic Classifiers, the Prosigna Breast Cancer Assay, and the Percepta Nasal Swab Test for lung cancer. Veracyte also offers the nCounter analysis system, an instrument-based service that supports gene expression research in clinical and translational settings.
As a precision diagnostics provider, Veracyte generates revenue primarily through the sale of its proprietary tests and the licensing of its analysis platform, with growth tied to physician adoption, payer reimbursement coverage, and ongoing expansion of its oncology-focused product portfolio.
- Decipher Prostate test revenue drives double-digit segment growth
- Medicare reimbursement decisions expand covered lives and test adoption
- Acquisitions broaden oncology test menu and international footprint
| Net Income: 88.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 4.81 > 1.0 |
| NWC/Revenue: 86.03% < 20% (prev 66.47%; Δ 19.56% < -1%) |
| CFO/TA 0.12 > 3% & CFO 166.2m > Net Income 88.0m |
| Net Debt (-399.7m) to EBITDA (112.2m): -3.56 < 3 |
| Current Ratio: 9.31 > 1.5 & < 3 |
| Outstanding Shares: last quarter (81.3m) vs 12m ago 1.57% < -2% |
| Gross Margin: 71.31% > 18% (prev 68.02%; Δ 3.29% > 0.5%) |
| Asset Turnover: 39.37% > 50% (prev 35.23%; Δ 4.15% > 0%) |
| Interest Coverage Ratio: 90.7k > 6 (EBIT TTM 90.7m / Interest Expense TTM 1.00k) |
| A: 0.32 (Total Current Assets 522.2m - Total Current Liabilities 56.1m) / Total Assets 1.44b |
| B: -0.24 (Retained Earnings -348.9m / Total Assets 1.44b) |
| C: 0.07 (EBIT TTM 90.7m / Avg Total Assets 1.38b) |
| D: 14.61 (Book Value of Equity 1.34b / Total Liabilities 92.0m) |
| Altman-Z'' = 17.12 = AAA |
| DSRI: 0.80 (Receivables 50.1m/53.8m, Revenue 541.7m/463.4m) |
| GMI: 0.95 (GM 68.02% / 71.31%) |
| AQI: 0.91 (AQ_t 0.60 / AQ_t-1 0.66) |
| SGI: 1.17 (Revenue 541.7m / 463.4m) |
| TATA: -0.05 (NI 88.0m - CFO 166.2m) / TA 1.44b) |
| Beneish M = -3.17 (Cap -4..+1) = AA |
As of July 11, 2026, the stock is trading at USD 56.97 with a total of 738,738 shares traded. Over the past week, the price has changed by -0.19%, over one month by +18.27%, over three months by +83.24% and over the past year by +107.01%.
Current recommended Stop Loss: 53.60 (which is 5.9% or 1.2 ATR below the current price).
Veracyte has received a consensus analysts rating of 4.36. Therefore, it is recommended to buy VCYT.
- StrongBuy: 8
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 50.6 | -11.2% |
P/E Trailing = 52.8519
P/E Forward = 34.8432
P/S = 8.4072
P/B = 3.5522
Revenue TTM = 541.7m USD
EBIT TTM = 90.7m USD
EBITDA TTM = 112.2m USD
Long Term Debt = 35.0m USD (estimated: total debt 39.3m - short term 4.35m)
Short Term Debt = 4.35m USD (from shortTermDebt, last quarter)
Debt = 39.3m USD (from shortLongTermDebtTotal, last quarter) (leases 39.3m already included)
Net Debt = -399.7m USD (calculated: Debt 39.3m - CCE 439.1m)
Enterprise Value = 4.15b USD (4.55b + Debt 39.3m - CCE 439.1m)
Interest Coverage Ratio = 90.7k (Ebit TTM 90.7m / Interest Expense TTM 1.00k)
EV/FCF = 26.84x (Enterprise Value 4.15b / FCF TTM 154.8m)
FCF Yield = 3.73% (FCF TTM 154.8m / Enterprise Value 4.15b)
FCF Margin = 28.58% (FCF TTM 154.8m / Revenue TTM 541.7m)
Net Margin = 16.25% (Net Income TTM 88.0m / Revenue TTM 541.7m)
Gross Margin = 71.31% ((Revenue TTM 541.7m - Cost of Revenue TTM 155.4m) / Revenue TTM)
Gross Margin QoQ = 72.32% (prev 74.43%)
Tobins Q-Ratio = 2.89 (Enterprise Value 4.15b / Total Assets 1.44b)
Interest Expense / Debt = 0.00% (Interest Expense 1.00k / Debt 39.3m)
Taxrate = 3.01% (2.73m / 90.7m)
NOPAT = 88.0m (EBIT 90.7m * (1 - 3.01%))
Current Ratio = 9.31 (Total Current Assets 522.2m / Total Current Liabilities 56.1m)
Debt / Equity = 0.03 (Debt 39.3m / totalStockholderEquity, last quarter 1.34b)
Debt / EBITDA = -3.56 (Net Debt -399.7m / EBITDA 112.2m)
Debt / FCF = -2.58 (Net Debt -399.7m / FCF TTM 154.8m)
Total Stockholder Equity = 1.28b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.40% (Net Income 88.0m / Total Assets 1.44b)
RoE = 6.86% (Net Income TTM 88.0m / Total Stockholder Equity 1.28b)
RoCE = 6.88% (EBIT 90.7m / Capital Employed (Equity 1.28b + L.T.Debt 35.0m))
RoIC = 6.48% (NOPAT 88.0m / Invested Capital 1.36b)
WACC = 9.56% (E(4.55b)/V(4.59b) * Re(9.64%) + D(39.3m)/V(4.59b) * Rd(0.00%) * (1-Tc(0.03)))
Discount Rate = 9.64% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 73.33 | Cagr: 4.84%
[DCF] Terminal Value 74.16% ; FCFF base≈124.3m ; Y1≈142.4m ; Y5≈209.6m
[DCF] Fair Price = 37.61 (EV 2.60b - Net Debt -399.7m = Equity 3.00b / Shares 79.8m; r=9.56% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 2.89 | # QB: 1
Revenue Correlation: 99.68 | Revenue CAGR: 20.13% | SUE: 2.27 | # QB: 5
EPS current Quarter (2026-06-30): EPS=0.43 | Chg30d=-0.46% | Revisions=+36% | Analysts=10
EPS next Quarter (2026-09-30): EPS=0.43 | Chg30d=-0.23% | Revisions=+0% | Analysts=10
EPS current Year (2026-12-31): EPS=1.82 | Chg30d=-0.16% | Revisions=+67% | GrowthEPS=+2.3% | GrowthRev=+13.3%
EPS next Year (2027-12-31): EPS=1.90 | Chg30d=-0.21% | Revisions=+67% | GrowthEPS=+4.4% | GrowthRev=+11.6%
[Analyst] Revisions Ratio: +55% (up=21, down=5)